!! Big Boards scans, charts and news !!

[MiamiGent]

Out without doubt. Retreating to my redoubt in Miami.

Will focus like locust on my ministry with the churches.

Had it with stocks..

Best to all!

MG

[lee kramer]

GENT: Buckner, Bruckner [for non New Yorkers it's a road: Bruckner Blvd.] and Schmuckner. Don't ask.

[MiamiGent]

CNBC | Morning Squawk

IN THE NEWS TODAY

U.S. stock futures were under pressure this morning. Wall Street closed sharply higher Wednesday, apparently taking as a vote of economic confidence the Fed's message keeping a December interest rate hike alive. (CNBC)

Ahead of today's trading, the Dow was within 44 points of getting back to breakeven for the year. But before the market opens, a host of companies report earnings and the government issues its first estimate of third quarter GDP. (CNBC)

U.S. oil prices were lower this morning, after surging 6.3 percent Wednesday on a government stockpiles report showing a rise within expectations and a drop in gasoline and distillate inventories. (Reuters)

In a change from previous debates, the candidates really got into the details of economic plans and entitlement programs, but exchanges grew contentious and political friendships were strained. (NY Times)

Emerging over Donald Trump as the front-runner in new national and Iowa polls, retired neurosurgeon Ben Carson said in the debate the U.S. would be better off replacing Medicare with individual savings accounts. (CNBC)

Trump, who's made combating illegal immigration a centerpiece of his outsider campaign, said in the debate that people can come to the U.S., but only if they do so legally. (CNBC)

The full House votes today on whether to make Rep. Paul Ryan, the 2012 vice-presidential nominee, the next speaker. He was nominated Wednesday by the GOP conference. (USA Today)

Pfizer (PFE) approached Botox-maker Allergan (AGN) to discuss what could be the biggest takeover deal this year. The healthcare sector has recently seen an unprecedented wave of deals. (WSJ)\

Deutsche Bank (DB) plans to cut 15,000 jobs and shed assets that employ some 20,000 other workers, as the new CEO starts to implement a deep overhaul. (Reuters)

Struggling since the financial crisis, Deutsche Bank is expected to announce soon that it will pay at least $200 million to resolve investigations into dealings with blacklisted countries. (NY Times)

London-based Barclays (BCS) today reported slightly worse-than-expected earnings, warned of a weaker end to 2015 , and said structural changes will be more expensive than previously expected. (CNBC)

Theranos authorized new shares at a valuation of more than $10 billion, just days before the Wall Street Journal raised questions about the lab startup. Meanwhile, the firm reduced the size of its board of directors. (WSJ & NY Times)

BY THE NUMBERS

In addition to the third quarter GDP number, the government also reports weekly jobless claims at 8:30 a.m. ET. Then at 10 a.m. ET, the National Association of Realtors is out with its September pending home sales report. And at 10:30 a.m. ET, the Energy Department releases its weekly look at natural gas inventories.

Earnings reports out this morning include numbers from Aetna (AET), MasterCard (MA), Charter Communications (CHTR), and Time Warner Cable (TWC). This afternoon, Starbucks (SBUX), LinkedIn (LNKD), and Electronic Arts (EA) lead the after-the-bell list.

Sony (SNE) today reported a fiscal second quarter profit, compared to a year earlier loss, thanks to healthy sales of its PlayStation 4 videogame consoles and its image sensors.

STOCKS TO WATCH

GoPro (GPRO) plunged in premarket trading, after missing by wide margins on earnings and revenue, as the action camera-maker saw lower than expected sales of its new wearable lines.

PayPal (PYPL), now separate from eBay (EBAY), was under pressure in the premarket, after revenue and full-year outlook matched forecasts. Earnings were above estimates, but perhaps didn't grow as much as expected.

Buffalo Wild Wings (BWLD) shares were lower in premarket trading, after earnings came in well below estimates. Revenue and forward guidance were also light.

Yelp (YELP) was higher in the premarket, as revenue beat forecasts. The online review site issued a wider-than-expected loss. Sales and marketing costs were higher in an effort to increase site traffic.

[lee kramer]

GENT: 'Reverse, Reverse, Perverse.' Oy, a poet who likes the rhyme we got here. I may have to come back at you. Soon.

[MiamiGent]

Yes, my use of reverse was perverse.

Been playing VRX-- hand to hand combat.

http://stockcharts.com/h-sc/ui?s=VRX

[maokin]

ok

[lee kramer]

'Reverse the reverse'? You be giving me a headache GENT.

[MiamiGent]

VRX This could reverse the reverse..
New daunting article (Bloomberg).
http://www.bloomberg.com/news/articles/2015-10-29/valeant-sales-web-emerged-after-druggist-flagged-mystery-scripts?cmpid=yhoo.headline

States take scripts very seriously.

[lee kramer]

Hi Mark. I had a few medical problems but I'm getting better.

You do what you gotta do.

[maokin]

Lee, as You likely remember, I have done many medical edits here in Okinawa; and as a layman, it became incumbent for me to learn to research that area.

I'm sorry to hear of illness in Your Family, and if You'd care to share the details, I'd be happy to take a look/see. I would have responded to You sooner, but I'd already used all of my fifteen daily posts.

Far be it from me to advise a long-time, experienced, trader like You, but I've watched AVXL since ~ $0.80, but like previous iterations, I've been stupid mao; and bought too little early on - now I must rely on being able to use margin properly.

I've been wrong many times in the past, but from all that I can see this stock is going very much higher than it is now - Needless to say, much depends on the new data released on Nov 7, (at THE most major such conference of the year), but Missling has consistently under-promised and over-delivered. This guy is one "clever cookie"; and the people he's chosen to surround himself with are not close to being "chopped liver." A look at management bios would be worthwhile - such guys would not risk their prestige and respect on anything less than this.

One of the reasons I was so late in accumulating was because I was reading historical postings. Not only does he over-deliver, but he delivers when it is least expected. I was accumulating pre-split, and quite suddenly the reverse split was announced - I needed but a couple of more days before social security would deliver me more powder - If the reverse split had come a couple days later, I would not be so dependent on margin as I am now.

From my perspective, my meager amount of shares is good enough for a homerun, but I need a grand slam homerun if I'm ever to escape this island or if not in time, leave Yumiko in reasonable comfort, after I'm gone.

If You ever want to discuss the stock or Your health concerns, please remember voice aka Skype is my preferred medium.

Your friend,

mark

[lee kramer]

Understood Mark. When I said AVXL looked higher I didn't mean right away. This one may take a while.

[maokin]

I know You want to short term trade it, Lee, but (with all due respect) two things to keep in mind:

Scheduled to ring the Nasdaq bell on Friday, and then

Major speaker at the premier Alzheimer's conference of the year on November 7th

(Got a double, now, and looking to add via margin at a propitious time)

Mid-session nap time.

[MiamiGent]

VRX I reversed and went long- short squeeze underway at this moment..

[MiamiGent]

VRX Valeant's Future Sales Become a New Focus

BY Dow Jones & Company, Inc. — 7:35 PM ET 10/27/2015
By Michael Rapoport And Jonathan D. Rockoff


When Valeant Pharmaceuticals International Inc. (VRX) defended its accounting and business practices to investors Monday, it said a pharmacy business comprised a relatively small portion of Valeant's revenues. If Valeant and the pharmacy broke ties, Valeant's growth may slow, but not "dramatically," Valeant's chief executive said.

Yet, the question of how important the pharmacy, Philidor Rx Services LLC, is to the Canadian drug maker's growth persisted Tuesday, with one ratings firm revising its outlook on Valeant bonds, citing Valeant's growth prospects in light of the controversy around Philidor. Some of the financial data Valeant disclosed Monday suggests its Philidor relationship has been a lucrative one, contributing to Valeant's revenue growth.

Philidor helps patients fill prescriptions for some of Valeant's drugs. Some analysts say Philidor helps patients who are prescribed Valeant drugs to get reimbursements for the medicines, rather than lower-cost alternatives sold by other companies that are preferred by insurers. Valeant purchased an option to buy Philidor in late 2014 and has been consolidating its results with its own since.

When investors learned of Valeant's relationship with Philidor last week, they sent Valeant shares down on concerns about accounting, which Valeant has defended, and questions about whether its work with Philidor would prove a sustainable business avenue.

Philidor on Monday said its "relationship with Valeant has benefited countless patients by ensuring they receive their medication quickly and efficiently," and that it is focused on "providing patients the medications their doctors want them to have."

Valeant has been under pressure to show it can run a business and grow organically rather than just through its signature approach of growth through acquisitions, and specialty pharmacies like Philidor appear to be an instrument for achieving that growth.

One example: Jublia, a toenail-fungus treatment that Valeant has touted as a reflection of its commitment to boosting its business through internal research and development. The treatment saw 44% of its revenue flow through Philidor in the third quarter, according to Valeant's presentation Monday.

Valeant has counted on Jublia for sales growth. Valeant has been advertising heavily for the drug, including running an ad during the Super Bowl that featured a fungus-fighting big toe wearing a football helmet.

Philidor comprises 5.9% of Valeant's revenues so far this year, according to Valeant. That percentage of Valeant's 2015 year-to-date revenues equals $455 million--versus $111 million in net sales that Philidor had for most of 2014.

Valeant's revenues are up 29% through the first nine months of 2015 compared with a year ago, to $7.71 billion from $5.98 billion.

The figures suggest Valeant's revenue growth could suffer if it ultimately decides to cut ties with Philidor--which Valeant has called a possibility--or if its ability to sell through Philidor proves less lucrative thanks to the controversy. Valeant said it would have "contingency plans" if it decides to cut ties.

"We do think this is material to the company's growth," said David A. Kaplan, a Standard & Poor's analyst, who on Tuesday revised his outlook on Valeant's junk-grade corporate credit rating to "negative" from "stable." In an email message, Mr. Kaplan said he has "had concerns for a long time about the sustainability" of Valeant's growth through its own business operations, rather than acquisitions.

In his report, he called Valeant's use of Philidor to reach consumers with pricey drugs "unconventional and very aggressive," and questioned whether insurers would continue to pay for Valeant drugs sold through the pharmacy. We " expect payers to increasingly push back on reimbursement, potentially reducing the viability of this channel."

Valeant's stock dipped about 0.5% on Tuesday after a drubbing over the past week. Valeant's 10-year bonds traded late Tuesday at 84.3 cents on the dollar, down slightly from Monday's late price of 85.5 cents.

On Monday, Valeant said the company created a committee of its directors to review issues surrounding Philidor and the other specialty pharmacies it uses.

Write to Michael Rapoport at [e-mail] and Jonathan D. Rockoff at [e-mail]

[MiamiGent]

[lee kramer]

AVXL 9.54. This puppy looks higher to me.

[MiamiGent]

AIG Icahn Takes ‘Large Stake’ in AIG, Encourages Split Into 3 Companies

Investor says insurer should separate life and mortgage insurance units from core property and casualty business

By
Chelsey Dulaney, WSJ
Updated Oct. 28, 2015 10:06 a.m. ET

http://stockcharts.com/h-sc/ui?s=AIG

Activist investor Carl Icahn said he has accumulated a “large stake” in American International Group Inc. and called for the insurer to split into three public companies.

In a letter to AIG Chief Executive Peter Hancock that Mr. Icahn posted on his website, he called for the global insurer to separate both its life and mortgage insurance units from its core property and casualty business, and embark on a “much needed cost control program.”

AIG shares climbed 3.6% in morning trading and are up 13% this year.

If split up, Mr. Icahn said each of the companies would be small enough to avert the “systemically important financial institution” designation.

AIG is one of three insurers that have been designated as systemically important by a panel of federal regulators created under the post-financial-crisis Dodd-Frank regulatory-overhaul law, and there is uncertainty about future capital levels these insurers will be required to hold.

In the letter, Mr. Icahn said AIG is too big to succeed, despite years of selling off non-core assets. He said the burdens of the systemically important designation, which include Federal Reserve oversight and increased capital requirements, hurt AIG’s returns and competitive position.

Mr. Hancock acknowledged in a statement that AIG received Mr. Icahn’s letter and said the company has taken significant steps to cut risk and sell noncore assets.

A representative for Mr. Icahn wasn’t immediately available for comment. The investor hasn’t yet made a regulatory filing disclosing the size of his stake in AIG and first disclosed his position in a tweet.

Mr. Icahn is famous for his strategy of targeting and publicly berating companies that he thinks are underperforming.

During the financial crisis, AIG became a poster child of the liquidity problems that hit many financial firms with exposure to subprime mortgage bonds after the real-estate bubble burst. In bailing out AIG, U.S. taxpayers at one point owned 92% of its equity. AIG fully repaid taxpayers by the end of 2012.

AIG has been on a several-year-long restructuring effort to improve profitability in its core business of selling property and casualty insurance to businesses. That business has faced headwinds recently amid pricing pressure and a strong dollar.

AIG has also been working to improve its returns under Mr. Hancock, who took the helm at AIG last year. The company has set a long-term goal of 10% return on equity.

In his letter, Mr. Icahn said AIG is lacking in cost controls and criticized the pace at which AIG is working to improve returns. “You must be proactive and commit to closing 100% of the [return on equity] gap between AIG and its peers,” he wrote in the letter.

In August 2013, AIG’s board decided to resume paying a common-stock dividend for the first time since the crisis. The company has also focused on buying back shares in recent periods to shrink the large number created in the wake of the 2008 government takeover.

AIG is due to report third-quarter results Monday.

Write to Chelsey Dulaney at [e-mail]

[lee kramer]

AVXL, not AVXLD. 9.27

[lee kramer]

Has AVXLD opened? I thought it was to open on the Naz today.

[MiamiGent]

CNBC | Morning Squawk

IN THE NEWS TODAY

U.S. stock futures were higher this morning, after another quiet session ahead of the Fed's policy statement at 2 p.m. ET. Central bankers are expected to leave the door open for an interest rate hike in December, but the market sees early next year as more likely. (CNBC)

Apple (AAPL) was higher in premarket trading, after posting earnings and revenue that topped expectations , boosted by strong iPhone growth in China. But the company was conservative on forward guidance. (CNBC)

Twitter (TWTR) plunged in the premarket, after reporting better-than-expected earnings and revenue but light guidance . Average monthly active users nudged higher to 307 million. (CNBC)

Walgreens Boots Alliance (WBA) has agreed to buy rival drugstore chain Rite Aid (RAD) for $9.4 billion , as many health care companies look to cut costs and consolidate amid industry changes like Obamacare. (CNBC)

Northrop Grumman (NOC) has won an Air Force contract, worth up to $80 billion, to build the next-generation long range bomber . Meanwhile, Boeing (BA), which had also been in contention, is deciding whether to appeal. (Reuters)

Volkswagen shares rallied in Germany today, despite reporting an operating loss of $3.84 billion in the third quarter, as a scandal over falsifying its diesel emissions knocked the automaker's results. (CNBC)

The FDA said beleaguered biotech unicorn Theranos is shipping the company's blood collection device without the proper authorization across state lines. (CNBC)

In a CNBC op-ed ahead of tonight's GOP presidential debate, candidate Donald Trump made his case for why voters should put him in the White House, citing his leadership skills.

Watch CNBC's "Your Money, Your Vote: The Republican Presidential Debate" tonight. The debate features two sets of candidates discussing critical issues facing America today, including job growth, taxes and the health of our economy. Coverage begins at 5 p.m. ET this evening.


The House is expected to vote today on a bipartisan, two-year budget deal supported by the White House. Meanwhile, House Republicans are set to nominate Rep. Paul Ryan as the new speaker. (USA Today)


Education officials said the drop in math scores on a nationwide test was unexpected, but could be related to changes ushered in by the Common Core standards. (NY Times)



BY THE NUMBERS

In a candid letter to investors, hedge fund billionaire Larry Robbins apologized for a 20 percent year-to-date loss in his flagship fund, writing, "I've failed to protect your capital, and mine ... despite a flat market."

U.S. oil prices gained ground this morning, after an industry group reported stockpiles declined at a key storage hub. Traders get a look at the weekly oil inventory numbers from the Energy Department at 10:30 a.m. ET.

Wide weekly swings in mortgage applications seem to have calmed down, now that new lender regulations have been in place for nearly a month. Total home loan filings decreased 3.5 percent last week, according to the Mortgage Bankers Association.

It's another busy morning for corporate earnings, with results Mondelez International (MDLZ) and Starwood Hotels (HOT), among others. The after-the-bell list this afternoon includes PayPal (PYPL), Yelp (YELP), and GoPro (GPRO).

Following the split of Hewlett-Packard into two separate companies, Hewlett Packard Enterprise (HPE) will be added to the S&P 500 after Friday's close, replacing Hudson City Bancorp, which is about to be acquired. HP Inc. (HPQ), keeping the legacy ticker symbol, will stay in the index.

STOCKS TO WATCH

Akamai (AKAM) shares were slammed in premarket trading, the Internet technology provider issued a profit and sales warning. However, current quarter earnings and revenue beat expectations. Akamai CEO Tom Leighton joins CNBC's "Squawk Box" at 7:40 a.m. ET.

Snack food maker Snyder's-Lance (LNCE) has agreed to buy Diamond Foods (DMND) for $1.27 billion. There were reports last week that Kellogg (K) had been in late-stage talks to purchase Diamond.

IBM (IBM) is near a deal to buy the digital assets of Weather Channel parent Weather Company, a deal that could be valued at more than $2 billion. Re/code had first reported the talks last week.

Jes Staley has been appointed as Barclays (BCS) new chief executive. The former JPMorgan executive's appointment is seen as a move to re-focus on the bank's investment banking operations.

[MiamiGent]

http://www.investing.com/indices/indices-futures

[MiamiGent]

http://www.investing.com/indices/indices-futures

[lee kramer]

Thanks GENT, got 'em.

[MiamiGent]

Futures http://finviz.com/futures.ashx

[MiamiGent]

TY for post maokin. It's OK with these bios- some of them start very humble and we want to catch 'em early.
I played this one last week successfully.

[MiamiGent]

GM Lee, Pls ck your email inbox for this weeks alerts

[HMB2010]

PR out: NASDAQ Wednesday - trades as "D" until then.

Anavex Announces Uplisting to NASDAQ



http://finance.yahoo.com/news/anavex-announces-uplisting-nasdaq-110000455.html

[maokin]

Some additional notes added to original message, Lee.

The action could be VERY interesting today - in the days leading up to today, there have been some bargains to be found as bashers and MMs have taken it down significantly (Buyers have stepped in each time) - I expect more of the same today.

Time for my pre-market nap - I hope this info has been of interest to ANYONE here.

[lee kramer]

Got it Mark, thanks.

[maokin]

AVXLD as it waits up-listing:

http://stockcharts.com/h-sc/ui?s=AVXLD&p=D&b=5&g=0&id=p79140321400

http://bigcharts.marketwatch.com/quickchart/quickchart.asp?symb=AVXLD&insttype=Stock

I consider this to be "ethical investing" at its finest - CEO Missling has Alzheimer's in his family - there are many clips of him on YouTube.

Since I've been following he has massively under-promised and equally massively over-delivered.

I suggest the Ihub board, and as previously mentioned officers' bios.

I was off a day on the uplist: http://investorshub.advfn.com/boards/read_msg.aspx?message_id=117983086

[lee kramer]

Hi Mark. I pull up a chart of AVXL and it shows only a close at 1.86 in early October.

[maokin]

I've wanted to alert THIS board to what I consider to be an extraordinary opportunity for a long time, but was wary of posting about it, as I did once previously post about a non-big board stock; but now I see "D" designated stocks seem to be OK.

AVXLD should be moving to NAZ today (Monday) or tomorrow (Tuesday).

SIXTEEN PhDs and M.D.s form the core of this group (these are prestigious men with prestigious backgrounds):

http://www.anavex.com/about-us/management_directors/

I know reverse splits are largely frowned upon, but this one was done from a position of strength, bringing the share count to under forty million.

In a rapidly aging world Alzheimer's is indeed a sweet spot to be.

The science behind the group lead the Michael J. Fox Foundation to donate ~ a quarter million dollars, as they believe this may also be effective in targeting Parkinson's. The last ten years have seen ONLY largely ineffective attempts to deal with Alxheimer's SYMPTOMS. Anavex Life's most recent clinical trial (protein unfolding) seems to indicate the disease, itself can be reversed.

World-wide, researchers are using the results obtained to see if they pertain to Diabetes, Epilepsy, Cancer, and other diseases.

Anavex has been awarded a prime time slot in the upcoming Clinical Trials on Alzheimer's Disease (CTAD) conference in Barcelona, Spain from November 5-7, 2015.

http://stockcharts.com/h-sc/ui?s=AVXLD&p=D&b=5&g=0&id=p85688520893

As You can see from the chart, I am not trolling, as volume remains extraordinary for such an equity. I have long wanted to share this equity here. As always, capital-challenged mao has only a relatively small position, here, but am + ONLY ~60% due to some VERY ill-timed buys.

http://investorshub.advfn.com/Anavex-Life-Sciences-Corp-AVXLD-11474/

http://www.anavex.com

[lee kramer]

Indeed you did GENT. Superlative call PACB. Thank you.

[MiamiGent]

Yup, I said it was going to go. More coming..

[lee kramer]

GENT: Your PACB is now 9.24 +1.11

[alexander77]

AMBS: target $45/share,wants to uplist to Nasdaq soon

Here is the analys report from SeethruEquity:
NEW YORK, NY / ACCESSWIRE / July 24, 2015 / SeeThruEquity, a leading independent equity research and corporate access firm focused on smallcap and microcap public companies, today announced it has initiated coverage of Amarantus BioScience Holdings, Inc. (AMBS) with a Price Target of $45.34.

The report is available here: AMBS Initiation Report. SeeThruEquity is an approved equity research contributor on Thomson First Call, Capital IQ, FactSet, and Zack's. The report will be available on these platforms. The firm also contributes its estimates to Thomson Estimates, the leading estimates platform on Wall Street.

Based in California, Amarantus BioScience Holdings (AMBSD) is a biotechnology company developing treatments and diagnostics neurology and orphan indications. As a biotechnology company, AMBS is developing treatments for wound healing, Parkinson's disease Levodopa-Induced Dyskinesia (PD-LID), Adult Attention Deficit Hyperactivity Disorder (ADHD), and Retinitis Pigmentosa, as well as developing better diagnostics to test for Alzheimer's disease and Multiple Sclerosis.

"AMBS has an impressive portfolio of product candidates across its diagnostic and therapeutic divisions. In particular, AMBS just recently announced that it has completed the acquisition of Cutanogen Corporation from Lonza Walkersville, Inc. a subsidiary of Lonza Group Ltd. Cutanogen has an exclusive worldwide license to intellectual property rights associated with Engineered Skin Substitute or ESS, a tissue-engineered skin replacement prepared from a patient's own skin cells. ESS has the potential to become a revolutionary treatment for severe burns and management believes that the path to approval for ESS could be rapid, potentially as quick as two years with market potential of $500 million," stated Ajay Tandon, CEO of SeeThruEquity. "We are initiating coverage with a 12-month price target of $45.34 per share."

Additional highlights from the report are as follows:

Strong Portfolio of Lead Products in Therapeutic Division: Engineered Skin Substitute (ESS), Eltoprazine and MANF

AMBS's therapeutic division's lead product candidates are ESS, Eltoprazine and Mesencephalic-astrocyte-derived neurotrophic factor (MANF). ESS is a combination of cultured epithelium with a collagen-fibroblast implant that produces a skin substitute that contains both epidermal and dermal components. ESS has received orphan drug designation from the U.S. Food and Drug Administration for the treatment of hospitalized patients with deep partial and full thickness burns requiring grafting. ESS is also being developed with support from the Armed Forces Institute for Regenerative Medicine (AFIRM). The AFIRM grant was initially worth $3mm with $0.75mm remaining and was awarded to support the IND and initial clinical studies. An IND with the US FDA is active, ESS has received orphan drug designation and a Phase 2 study is expected to open in 3Q15. Key catalysts in this program are around acceleration of the regulatory timeline as well as clinical data expected to come on a per patient basis given the special nature of the trial being initiated at a US military clinical site.

Eltoprazine is a small molecule 5HT1a/1b partial agonist in clinical development for the treatment of Parkinson's disease levodopa-induced dyskinesia (PD-LID), Adult ADHD, and Alzheimer's Aggression. Eltoprazine has been evaluated in over 600 human subjects to date, and has shown a strong and well established safety profile, as well as initial proof of concept data funded by the Michael J. Fox Foundation and published in the journal BRAIN. AMBS is expecting to have Phase 2b program clinical data in the first half of 2016 for Eltoprazine treatment in PD-LID.

MANF is believed to have broad potential because it is a naturally occurring protein produced by the body for the purpose of reducing and preventing apoptosis (cell death) in response to injury or disease. AMBS is the front-runner and primary holder of intellectual property around MANF, and is focusing on the development of MANF-based protein therapeutics. MANF has demonstrated efficacy as a disease-modifying treatment in various animal models, including retinitis pigmentosa, Parkinson's disease, cardiac ischemia and stroke. AMBS has also received European Union Orphan Drug Destination for MANF for the treatment of retinitis pigmentosa (RP). Amarantus expects to initiate human clinical studies in the second half of 2016 in RP.

Neuro-diagnostic division seeks to enhance the industry standard

AMBS's diagnostics division's lead developments are the MSPrecise(R) and the LymPro Test(R). MSPrecise(R) is a proprietary next-generation DNA sequencing (NGS) assay for the identification of patients with relapsing-remitting multiple sclerosis (RRMS) at first clinical presentation. MSPrecise(R) utilizes next-generation sequencing to measure DNA mutations found in rearranged immunoglobulin genes in immune cells initially isolated from cerebrospinal fluid.The Lymphocyte Proliferation Test, LymPro, is a diagnostic blood test for Alzheimer's disease that works by evaluating the cell surface marker CD69 on peripheral blood lymphocytes following a mitogenic stimulation. If the CD69 is not up-regulated when measured, it means there is a dysfunctional cellular machinery division process, and Alzheimer's is more likely to be present. To help fuel the advancement of their Therapeutics pipeline, management has indicated they are evaluating strategic exit opportunities for their diagnostics division including potentially selling off the division, spinning off the division into its own company, or licensing the technologies to a third party.

PhenoGuard(TM) shows strong potential to further Drug Division

PhenoGuard(TM) is a proprietary discovery technology that played an essential role to developing MANF. Going forward, management believes that this drug discovery platform can be used to discover other, similar neurotrophic factors. The PhenoGuard(TM) technology currently consists of 88 cell lines, and management intends to expand the number of such cell lines through additional research.

Please review important disclosures on our website at www.seethruequity.com.

http://finance.yahoo.com/news/seethruequity-initiates-coverage-amarantus-bioscience-130000691.html

[lee kramer]

PACB 7.05. Buying Dec 19 calls.

[MiamiGent]

Futures http://finviz.com/futures.ashx

[MiamiGent]

CNBC | Morning Squawk

IN THE NEWS TODAY

U.S. stock futures were higher this morning, with Wall Street trying to avoid its first three-session losing streak of October. Investors get plenty to consider today, including earnings, U.S. economic reports, and a policy statement from the European Central Bank. (CNBC)

Dow components 3M (MMM), McDonald's (MCD), and Caterpillar (CAT) lead this morning's earnings list, with Google parent Alphabet (GOOGL), Amazon, (AMZN), and Dow stock Microsoft (MSFT) out after the bell. (CNBC)

AT&T (T), also out with earnings this afternoon, warned about revenue, saying analyst projections were inflated because of discrepancies involving the accounting for AT&T's recent acquisition of DirecTV. (CNBC)

American Express (AXP), a Dow stock, late Wednesday missed on earnings and revenue. Cautious spending by customers was a key factor, as average transaction levels fell by 3 percent. (CNBC)

Now separate from PayPal, eBay (EBAY) late Wednesday beat on earnings and matched forecasts on revenue. The e-commerce giant boosted its profit forecast and gave an upbeat holiday season outlook. (Reuters)

Already Valeant's (VRX) third-largest shareholder, hedge fund manager Bill Ackman bought an additional 2 million shares of the company, as its stock plunged following the release of an explosive short-seller note. (CNBC)

Yahoo (YHOO) is cutting advertising rates for the first-ever web-streamed NFL game this coming Sunday. The cost is now said to be less than $100,000, down from the initial $200,000. (Reuters)

Nearly three weeks after soundly rejecting a tentative agreement, voting at Fiat Chrysler (FCAU) plants is showing support for a new contract to enable entry-level wage parity. Final results are due later today. (NY Times)

Apple (AAPL) is planning to build 200 megawatts worth of solar projects in China, while pushing its suppliers to go green amid ongoing criticism that its local partners cause heavy pollution. (CNBC)

Hess CEO John Hess told CNBC the seeds have been planted for a slow oil recovery. Meanwhile, U.S. oil prices were higher this morning, after dropping about 2.4 percent Wednesday on higher inventories.

A supermajority of firebrand conservatives in the House are supporting the reluctant Rep. Paul Ryan to be the next speaker, saying they've provided him enough votes to win the race. (Reuters)

Democratic presidential frontrunner Hillary Clinton is set to testify before the House Select Committee on Benghazi today to defend her actions dealing with the 2012 attacks while she was secretary of state. (USA Today)

The chairman of the Commodity Futures Trading Commission has signaled the first serious effort to curb high-speed trading, which increasingly influences benchmark assets. (FT)

Daily fantasy-sports site DraftKings has received a subpoena from U.S. Attorney Preet Bharara's office, requesting information about an employee's activities and potential abuse of inside data. (WSJ)

BY THE NUMBERS

The European Central Bank's latest meeting culminates with its statement at 7:45 a.m. ET, and a news conference with ECB President Mario Draghi at 8:30 a.m. ET. No change in interest rates is expected, though investors will key on any clues to future monetary easing.

In the U.S., the Labor Department issues its weekly report on first-time unemployment benefits at 8:30 a.m. ET. Forecasts call for 265,000 new jobless claims for the week ending Oct. 17, which would be 10,000 more than the prior week.

The National Association of Realtors is out with its September existing home sales report at 10 a.m. ET, with expectations for a 1.7 percent increase following a 4.8 percent decline in August.

The Conference Board, also at 10 a.m. ET, releases its September index of leading economic indicators. The LEI is seen unchanged after a 0.1 percent increase in August.

Other earnings out this morning include Dow Chemical (DOW), Dunkin' Brands (DNKN), Eli Lilly (LLY), Sirius XM (SIRI), Southwest Airlines (LUV), United Continental (UAL), and Under Armour (UA).

Billionaire David Einhorn, whose Greenlight Capital hedge fund is nursing a 17 percent loss this year, told investors about new bets on fashion house Michael Kors (KORS) and electric services firm UIL (UIL).

STOCKS TO WATCH

Texas Instruments (TXN) earned 76 cents per share, 9 cents above estimates, with revenue also beating forecasts. The chipmaker was helped by better sales for its analog and embedded chip offerings.

Citrix Systems (CTXS) saw quarterly profit come in 20 cents above estimates at an adjusted $1.04 per share, and the software maker also scored a significant beat on the revenue side.


Las Vegas Sands (LVS) beat estimates by 2 cents with quarterly profit of 66 cents per share, but the casino operator's revenue was below forecasts on weakness in its Macau operations.


CIT Group (CIT) said CEO John Thain will retire in March, to be replaced by long-time banking executive Ellen Alemany. Thain took over at CIT in 2010 following the commercial lender's bankruptcy.


Visa (V) raised its dividend by 17 percent, increasing it to 14 cents per share from 12 cents. The credit card giant had boosted the pay-out by 20 percent last year, and by 21 percent the year before.


Comcast (CMCSA) plans to resell Verizon's wireless service, according to Re/code, in what is seen as a move for the NBCUniversal and CNBC parent to offer its own wireless service.

[lee kramer]

AAPL apologizes for sharing personal information with others. Apology not accepted in my neighborhood.

[lee kramer]

IBM 138.58. May bounce in a while but this chart looks lower.

[lee kramer]

IBM 140.99. Ouch. Profit problems.Looks lower from where I'm sitting.

[MiamiGent]

CNBC | Morning Squawk

IN THE NEWS TODAY

U.S. stock futures were lower this morning, due in part to a disappointing earnings report from Dow stock IBM (IBM). Closing modestly higher, Wall Street on Monday wiped out early losses on Morgan Stanley's downbeat quarter. (CNBC)

Earnings this morning feature three more Dow components: United Technologies (UTX), Travelers (TRV), and Verizon (VZ). Meanwhile, Chipotle Mexican Grill (CMG) and Yahoo (YHOO) report after the bell. (CNBC)

IBM shares were sharply lower in premarket trading after announcing revenues that missed even the most pessimistic expectations and issuing weaker-than-expected guidance for the year. The latest earnings beat estimates. (CNBC)

Warren Buffett's Berkshire Hathaway, which according to its latest filing owned 79.57 million shares of IBM as of June 30, saw paper losses of more than $500 million on Big Blue's stock decline. (CNBC)

Yum Brands (YUM), behind KFC, Pizza Hut, and Taco Bell, plans to separate its China and U.S. businesses into two independent, publicly traded companies. (CNBC)

Apple's (AAPL) new streaming music service has more than 6.5 million paid users , with another 8.5 million on free trials, said CEO Tim Cook, speaking at a Wall Street Journal tech event. He also talked about the Apple Watch, Apple TV, and car rumors.

Amazon (AMZN) is creating 100,000 seasonal jobs to deal with increased demand for the upcoming holiday shopping season . That's in addition to hiring 25,000 full-time jobs in recent months. (CNBC)

United Continental (UAL) has named its general counsel Brett Hart as acting chief executive, as well as confirming reports that new CEO Oscar Munoz suffered a heart attack last week. (CNBC)

DraftKings said an independent investigation has found that one of its employees did not use inside information to win $350,000 from rival fantasy sports site FanDuel. (NBC News)

Oscar Pistorius has been released on parole, just short of a year into his five-year sentence for killing his girlfriend Reeva Steenkamp. South Africa's "Blade Runner" still faces house arrest and a prosecutor appeal. (Reuters) (note by MG: A travesty of justice and example of the power of celebrity)


Federal officials are looking into reports that a personal AOL email account belonging to CIA Director John Brennan may have been hacked by a high school student. (NBC News)

Donald Trump still led all GOP presidential rivals with 25 percent support, according to the latest NBC News/Wall Street Journal poll. Meanwhile, Ben Carson remained in second place with 22 percent.

Jim Webb, who complained about time repeatedly during the first Democratic presidential debate, is considering running as an independent. (USA Today)

Mired in anemic economic growth, Canada voted in liberal Justin Trudeau, son of a former prime minister, delivering a stunning defeat to the current conservative Prime Minister Stephen Harper. (CNBC & Reuters)

BY THE NUMBERS

Fed Chair Janet Yellen gives opening remarks at a Labor Department event at 11 a.m. ET in Washington, D.C., while New York Fed President William Dudley and Fed Gov. Jerome Powell speak in New York City at 9:15 a.m. ET.

The Commerce Department releases housing starts and building permits for September at 8:30 a.m. ET, with forecasts calling for a starts increase of 1.8 percent after a 3.0 percent decline in August. Permits were expected to be unchanged last month after rising 2.7 percent in August.

While a new survey National Retail Federation found consumers plan to spend roughly the same amount this holiday season, they're planning to shell out 4 percent more on themselves and non-gift items.

In earnings news: Rambus (RMBS) was getting crushed in the premarket this morning, after the chipmaker late Thursday reported weaker-than-expected revenue and forward guidance. The company did, however, match estimates on earnings.

Sonic (SONC) soared in premarket trading, after the drive-in restaurant chain beat estimates on earnings and revenue. Same-store sales increased 7.3 percent.

STOCKS TO WATCH

Amsurg (AMSG) is offering to buy Team Health (TMH) for $71.47 per share in cash and stock, but Team Health has rebuffed the bid. The companies provide outsourced physician services to hospitals

Aetna's (AET) proposed acquisition of rival health insurer Humana (HUM) was approved by shareholders of both companies, and the deal is expected to close in the second half of 2016.

SanDisk (SNDK) is in advanced talks to be acquired by disk drive maker Western Digital (WDC), according to multiple reports. In other possible deal, Blackstone (BX) is said to be near a deal to buy New York City apartment complex Stuyvesant Town-Peter Cooper Village for about $5.3 billion.

Releasing details of its Civic redesign for 2016, Honda (HMC) said the new sedan, which is slightly bigger and lighter, gets more than 40-mile-per-gallon in highway driving.

Looking to help European brands sell into China, Alibaba (BABA) has appointed country-specific managers to run its offices in U.K. and Italy. Alibaba's move coincides with Chinese President Xi Jinping's visit to Britain.

The new Hershey's Kisses Deluxe, double the size of standard Kisses, goes on sale in the U.S. next month, the chocolate maker announced today. The product originally launched in China in 2013.

[MiamiGent]

Futures http://finviz.com/futures.ashx

[lee kramer]

"IBM sales continue to fall." Stock looks lower still, to me.

[MiamiGent]

CNBC | Morning Squawk

IN THE NEWS TODAY

U.S. stock futures were lower this morning, after Wall Street capped a third straight winning week. The market drivers this week include the accelerating pace of quarterly earnings. (CNBC)

Morgan Stanley (MS) is among this morning's profit reports, reporting a miss on the top and bottom lines. Meanwhile, Dow component IBM (IBM) leads this afternoon's after-the-bell list.

China said its economy expanded at the slowest pace since the financial crisis: up 6.9 percent in the third quarter, better than the expected 6.8 percent but down from 7 percent in the previous period. (CNBC)

Oil prices dropped this morning on the China GDP figures, which sparked concerns about demand. Traders are also watching as President Barack Obama on Sunday officially put the Iran nuclear deal into effect. (Reuters)

Deutsche Bank (DB) has announced a sweeping reorganization, with the German financial giant splitting its investment bank in two and parting ways with some of its key executives. (CNBC)

A high-profile U.S. investigation of bribery allegations against the Mexican operations of Wal-Mart (WMT) has found little in the way of major offenses, and could be resolved with a fine and no criminal charges. (WSJ)

The daily fantasy sports website DraftKings accepted entries into its contests for the weekend, apparently defying an order from the Nevada Gaming Control Board to quit operating immediately within the state. (NY Times)

Apple (AAPL) was ordered to pay more than $234 million to the University of Wisconsin's patent licensing arm for infringing its patent on microchip technology used in some of Apple's iPhones and iPads. (AP)

Amazon (AMZN) has filed suit against hundreds of people for publishing "false, misleading and inauthentic" reviews on its website. It appears to be an extension of action take earlier this year. (Telegraph)

Google-owned YouTube is readying a slate of programming, set to be announced next week, that will only be available to users who join its upcoming subscription services. (Re/code)

After a glitzy roadshow, Ferrari's long-awaited IPO will likely be priced tomorrow, with its first day of trading on the New York Stock Exchange expected Wednesday. (NY Times)

Match Group, behind of dating services such as Match.com, Tinder, and OkCupid, has filed with regulators for an IPO. Match is owned by media mogul Barry Diller's IAC/InterActive (IACI). (Reuters)

Congress gets back from a week-long break today, with another showdown over raising the debt ceiling looming. Last week, Treasury Secretary Jack Lew said Congress needs to act by Nov. 3. (USA Today)

Treasury Secretary Jack Lew told CNBC today he worries that waiting until the last minute to raise the nation's borrowing authority could result in a terrible accident. (CNBC)

GOP presidential candidate Rand Paul, struggling in the polls, blamed what he calls the "celebrity culture" in the nation for leading to the rise of frontrunner Donald Trump. (CNBC)

BY THE NUMBERS

Ahead of next week's October meeting of Fed policymakers, the National Association of Home Builders is out with its October sentiment index at 10 a.m. ET, with expectations for a read of 62, unchanged from the September reading.

Third-quarter growth targets for the U.S. economy average 1.6 percent, according to a CNBC/Moody's Analytics survey, with some forecasts as low as 1 percent after Q2 GDP grew at a 3.9 percent pace.

It's another busy day for Fed-related appearances, with speeches today from Fed Gov. Lael Brainard, Chicago Fed President Charles Evans, and Richmond Fed President Jeffrey Lacker.

STOCKS TO WATCH

Aetna (AET) and Humana (HUM) are putting their $37 billion merger plan to a vote by investors. ISS and Glass Lewis are advising support for the deal. Results are expected this afternoon.

Valeant Pharmaceuticals (VRX) beat estimates by 4 cents with adjusted quarterly profit of $2.74 per share. Revenue was slightly below forecasts, but Valeant did raise its full-year forecasts for both revenue and profit.

Shire (SHPG) failed to receive FDA approval for its dry eye disease drug Lifitegrast, with the agency recommending the company conduct more clinical studies.

JPMorgan Chase (JPM) and Morgan Stanley will pay more than half of a $1.86 billion settlement in a swaps price-fixing case, according to a court filing.

ATM maker Diebold (DBD), based in Ohio, is offering to take over Nixdorf in a deal that would value the German company at more than $1.9 billion.

IBM is in advanced talks to buy the digital assets of the Weather Channel, according to Re/code. The service is owned by two private equity firms and NBCUniversal. Comcast owns NBC and CNBC.

AT&T (T), Verizon (VZ), and other telecom companies are being investigated by the FCC for alleged anticompetitive practices, centering on pricing plans for business data services.

Shares of Weight Watchers (WTW) soared in premarket trading after the weight loss company said Oprah Winfrey is taking a 10 percent stake and will join the board of directors.

There's been no new information from United Continental (UAL) since Thursday's hospitalization of new CEO Oscar Munoz. He reportedly suffered a heart attack.

[MiamiGent]

Good morning, Lee- a reminder to check your email inbox for this week alerts, released before market, this morning.
As this was first transmission, please check it reached you.
Picks doing very well this morning.
MG

[lee kramer]

Tom Yawkey was a racist. He paid his players what he chose. Curt Flood changed the game and gave up his career when he challenged the Reserve Clause. He won... The Iron Horse had a massive year for the Yankees. Massive! He came in and was told he'd have take take a $5,000 pay cut. He had no choice.

It's a better game now.

[MiamiGent]

Contest closed- no winners.

To my friends, ihubbers and die-heart Red Sox fans Rudolphvincent and Lee Kramer, I only have one thing to say,

tsk, tsk, tsk.

lol

Tom Yawkey was the immensely well liked gentleman owner of the Red Sox for the years of my youth and adulthood. When he passed, his wife Jean took over and exerted the same benevolent, "hands off" manner of her husband Tom.
Tom and Jean wintered in South Carolina, eventually bequeathing an enormous coastal wildlife reserve to the State of Carolina, as seen on the map for the contest.



MiamiGent Member Level Tuesday, 10/13/15 11:57:06 AM
RT 95 in South Carolina has been closed for at least a week due to flooding. Traffic diverted at RT 26 exit to Columbia, S.C. and then I20 to Florence to get back on 95. Big detour! Took opportunity to explore Charleston and Mt Pleasant, which was exceedingly pleasant but I discerned no mount- unless you count the ramp up the Ravenel Bridge https://www.google.com/search?q=charleston+sc+bridge&gws_rd=ssl
Be the first to identify the Red Sox in this map and receive 12 months of my alerts https://www.google.com/maps/place/Francis+Marion+National+Forest/@32.8977556,-80.0406392,10z/data=!4m2!3m1!1s0x0000000000000000:0xa36f0dc6f5a1aea5

[MiamiGent]

GM Lee, 8.44 high in P-M, 8.35 last.